A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Ipilimumab (Primary) ; Cetuximab
- Indications Head and neck cancer
- Focus Adverse reactions; Biomarker
- 19 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jan 2016 Planned End Date changed from 1 Oct 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 27 May 2013 New trial record